Tepotinib is another nonselective c-MET inhibitor that is being investigated in a Phase II study (NCT04647838) in patients with solid cancers harboring c-MET amplification or exon 14 mutation who progressed after standard treatment for metastatic disease, including mCRC. Here, MET is linked to metastatic neoplasm.